NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free CUE Stock Alerts $1.89 +0.05 (+2.72%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.85▼$1.9450-Day Range$1.77▼$2.8452-Week Range$1.70▼$5.12Volume192,115 shsAverage Volume262,704 shsMarket Capitalization$85.28 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cue Biopharma alerts: Email Address Cue Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside270.4% Upside$7.00 Price TargetShort InterestBearish9.13% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews Sentiment0.47Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.17) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 starsMedical Sector331st out of 938 stocksPharmaceutical Preparations Industry145th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingCue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Cue Biopharma has a forecasted upside of 270.4% from its current price of $1.89.Amount of Analyst CoverageCue Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.13% of the outstanding shares of Cue Biopharma have been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Cue Biopharma has recently increased by 3.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCue Biopharma has received a 74.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cue Biopharma is -0.58. Previous Next 3.0 News and Social Media Coverage News SentimentCue Biopharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cue Biopharma this week, compared to 1 article on an average week.Search Interest5 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows5 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders10.24% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.04% of the stock of Cue Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($1.17) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Cue Biopharma Stock (NASDAQ:CUE)Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More CUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CUE Stock News HeadlinesMarch 13, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Silence TherapeuticsFebruary 29, 2024 | finance.yahoo.comCue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumMarch 28, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 29, 2024 | globenewswire.comCue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumFebruary 27, 2024 | morningstar.comCue Biopharma Inc Ordinary SharesFebruary 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)February 6, 2024 | finance.yahoo.comCue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | finance.yahoo.comCue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionJanuary 17, 2024 | finance.yahoo.comCue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years agoDecember 14, 2023 | investorplace.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023December 7, 2023 | finance.yahoo.comAre Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?November 22, 2023 | finance.yahoo.comCue Biopharma to Present at the JMP Securities Hematology and Oncology SummitNovember 12, 2023 | finance.yahoo.comCue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | msn.comCue Biopharma reports Q3 resultsNovember 10, 2023 | finance.yahoo.comCue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 9, 2023 | finance.yahoo.comCue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 8, 2023 | morningstar.comCue Biopharma Inc Ordinary Shares CUENovember 7, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Mirati Therapeutics (MRTX)November 7, 2023 | finance.yahoo.comCue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in NovemberNovember 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cue Biopharma (CUE), Zoetis (ZTS) and CymaBay Therapeutics (CBAY)November 3, 2023 | finance.yahoo.comCue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023September 28, 2023 | finance.yahoo.comAcadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?September 27, 2023 | finance.yahoo.comCue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 26, 2023 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDASeptember 26, 2023 | finance.yahoo.comCue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®August 30, 2023 | benzinga.comCue Biopharma And 2 Other Stocks Under $3 Insiders Are BuyingSee More Headlines Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today3/28/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CUE CUSIPN/A CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+270.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,010,000.00 Net Margins-1,358.43% Pretax Margin-1,358.40% Return on Equity-99.14% Return on Assets-65.89% Debt Debt-to-Equity Ratio0.12 Current Ratio3.34 Quick Ratio3.34 Sales & Book Value Annual Sales$1.25 million Price / Sales68.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book1.24Miscellaneous Outstanding Shares45,120,000Free Float40,502,000Market Cap$85.27 million OptionableOptionable Beta2.04 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Daniel R. Passeri J.D. (Age 63)M.Sc., CEO & Director Comp: $985.72kDr. Anish Suri Ph.D. (Age 50)President & Chief Scientific Officer Comp: $641.98kMs. Kerri-Ann Millar (Age 54)Chief Financial Officer Comp: $559.03kDr. Ronald D. Seidel III (Age 48)Ph.D., Co-Founder Comp: $316.63kDr. Rodolfo J. Chaparro (Age 51)Co-Founder & Senior Advisor Comp: $316.63kDr. Steven C. Almo (Age 63)Co-Founder and Chairman of Scientific & Clinical Advisory Board George B. Zavoico Ph.D.VP of Investor Relations & Corporate DevelopmentMr. Colin G. Sandercock J.D. (Age 67)MSE, Senior VP, General Counsel & Secretary Comp: $381.42kDr. Matteo Levisetti M.D. (Age 55)Chief Medical Officer More ExecutivesKey CompetitorsVaxxinityNASDAQ:VAXXAclaris TherapeuticsNASDAQ:ACRSTempest TherapeuticsNASDAQ:TPSTVeruNASDAQ:VERURezoluteNASDAQ:RZLTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 7,999 shares on 3/11/2024Ownership: 4.727%Goldman Sachs Group Inc.Bought 39,211 shares on 3/1/2024Ownership: 0.129%GSA Capital Partners LLPBought 13,952 shares on 2/16/2024Ownership: 0.031%Vanguard Group Inc.Bought 7,999 shares on 2/15/2024Ownership: 4.727%Citadel Advisors LLCSold 6,000 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CUE Stock Analysis - Frequently Asked Questions Should I buy or sell Cue Biopharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CUE shares. View CUE analyst ratings or view top-rated stocks. What is Cue Biopharma's stock price target for 2024? 2 Wall Street research analysts have issued twelve-month price objectives for Cue Biopharma's shares. Their CUE share price targets range from $6.00 to $8.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View analysts price targets for CUE or view top-rated stocks among Wall Street analysts. How have CUE shares performed in 2024? Cue Biopharma's stock was trading at $2.64 at the start of the year. Since then, CUE shares have decreased by 28.4% and is now trading at $1.89. View the best growth stocks for 2024 here. When is Cue Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our CUE earnings forecast. How can I listen to Cue Biopharma's earnings call? Cue Biopharma will be holding an earnings conference call on Monday, April 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) posted its earnings results on Tuesday, May, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. The firm had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.30 million. Cue Biopharma had a negative trailing twelve-month return on equity of 99.14% and a negative net margin of 1,358.43%. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD). Who are Cue Biopharma's major shareholders? Cue Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.73%), Vanguard Group Inc. (4.73%), Dimensional Fund Advisors LP (1.02%), Northern Trust Corp (0.85%), Monaco Asset Management SAM (0.76%) and Stifel Financial Corp (0.43%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Daniel R Passeri, Kerri-Ann Millar and Peter A Kiener. View institutional ownership trends. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CUE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.